Table 2. GSEM results for likelihood of developing severe dengue disease on days 2 and 3 of enrolment.
| Baseline co-variates | Study Day 2 (n = 438) aOR (95% CI) | Study Day 3 (n = 399) aOR (95% CI) |
| Age | 1.03 (1–1.06)* | 1.05 (1.00–1.10)* |
| Gender | ||
| Male | Reference | |
| Female | 1.48 (0.68–3.23) | 1.08 (0.32–3.65) |
| Ethnicity | ||
| Chinese | Reference | |
| Malay | 0.59 (0.07–4.96) | 2.14 (0.15–30.07) |
| Indian | 0.14 (0.02–1.06) | 0.24 (0.03–1.95) |
| Others | 0.59 (0.07–4.90) | 2.70 (0.24–30.73) |
| Charlson’s co-morbidity score | ||
| 0 | Reference | |
| ≥1 | 1.51 (0.25–8.91) | 1.56 (0.12–21.20) |
| Fever at presentation | ||
| No | Reference | |
| Yes | 6.76 (1.41–32.4)* | 0.77(0.17–3.60) |
| Fever duration in days | 1.29 (0.96–1.73) | 1.27 (0.82–1.97) |
| Fever on Study day 2 | ||
| No | Reference | |
| Yes | 1.93 (0.85–4.37) | 0.54 (0.18–1.62) |
| Fever on Study day 3 | ||
| No | NA | Reference |
| Yes | NA | 3.97 (1.18–13.34)* |
| Pain score at presentation | 0.96 (0.83–1.10) | 1.09 (0.90–1.32) |
| Study Day 2 pain score | 0.96 (0.82–1.13) | 1.15 (0.92–1.42) |
| Study Day 3 pain score | NA | 3.97 (1.18–13.34)* |
*Statistically significant; equivalent to p<0.05.